Phase II evaluation of high-dose intravenous cisplatin for treatment of adult malignant gliomas recurrent after chloroethylnitrosourea failure

Alexander M. Spence, Mitchel S. Berger, Robert B Livingston, Francis Ali-Osman, Brian Griffin

Research output: Contribution to journalArticle

44 Citations (Scopus)

Abstract

Twenty-one patients with recurrent malignant glioma who had failed prior chemotherapy with nitrosoureas were treated with high-dose intravenous cisplatin on days 1 and 8 of successive 4 week cycles. Fourteen patients were evaluable for response. Four patients showed partial responses; mean time to tumor progression (MTP) was 8 weeks. Six patients stabilized; MTP was 11 weeks. Four patients showed no response. There were no infectious or hemorrhagic complications, but partial hearing loss occurred in 7 patients and severe vomiting in 8 patients. High-dose intravenous cisplatin demonstrates substantial activity against malignant gliomas recurrent after chloroethylnitrosourea (CENU) failure.

Original languageEnglish (US)
Pages (from-to)187-191
Number of pages5
JournalJournal of Neuro-Oncology
Volume12
Issue number2
DOIs
StatePublished - Feb 1992
Externally publishedYes

Fingerprint

Glioma
Cisplatin
Therapeutics
Hearing Loss
Vomiting
Drug Therapy
Neoplasms

Keywords

  • astrocytoma
  • brain tumors
  • chemotherapy
  • cisplatin
  • glioblastoma
  • malignant glioma

ASJC Scopus subject areas

  • Neuroscience(all)
  • Oncology
  • Clinical Neurology
  • Cancer Research

Cite this

Phase II evaluation of high-dose intravenous cisplatin for treatment of adult malignant gliomas recurrent after chloroethylnitrosourea failure. / Spence, Alexander M.; Berger, Mitchel S.; Livingston, Robert B; Ali-Osman, Francis; Griffin, Brian.

In: Journal of Neuro-Oncology, Vol. 12, No. 2, 02.1992, p. 187-191.

Research output: Contribution to journalArticle

@article{1660074a027848eb832d28f7b9b2747d,
title = "Phase II evaluation of high-dose intravenous cisplatin for treatment of adult malignant gliomas recurrent after chloroethylnitrosourea failure",
abstract = "Twenty-one patients with recurrent malignant glioma who had failed prior chemotherapy with nitrosoureas were treated with high-dose intravenous cisplatin on days 1 and 8 of successive 4 week cycles. Fourteen patients were evaluable for response. Four patients showed partial responses; mean time to tumor progression (MTP) was 8 weeks. Six patients stabilized; MTP was 11 weeks. Four patients showed no response. There were no infectious or hemorrhagic complications, but partial hearing loss occurred in 7 patients and severe vomiting in 8 patients. High-dose intravenous cisplatin demonstrates substantial activity against malignant gliomas recurrent after chloroethylnitrosourea (CENU) failure.",
keywords = "astrocytoma, brain tumors, chemotherapy, cisplatin, glioblastoma, malignant glioma",
author = "Spence, {Alexander M.} and Berger, {Mitchel S.} and Livingston, {Robert B} and Francis Ali-Osman and Brian Griffin",
year = "1992",
month = "2",
doi = "10.1007/BF00172671",
language = "English (US)",
volume = "12",
pages = "187--191",
journal = "Journal of Neuro-Oncology",
issn = "0167-594X",
publisher = "Kluwer Academic Publishers",
number = "2",

}

TY - JOUR

T1 - Phase II evaluation of high-dose intravenous cisplatin for treatment of adult malignant gliomas recurrent after chloroethylnitrosourea failure

AU - Spence, Alexander M.

AU - Berger, Mitchel S.

AU - Livingston, Robert B

AU - Ali-Osman, Francis

AU - Griffin, Brian

PY - 1992/2

Y1 - 1992/2

N2 - Twenty-one patients with recurrent malignant glioma who had failed prior chemotherapy with nitrosoureas were treated with high-dose intravenous cisplatin on days 1 and 8 of successive 4 week cycles. Fourteen patients were evaluable for response. Four patients showed partial responses; mean time to tumor progression (MTP) was 8 weeks. Six patients stabilized; MTP was 11 weeks. Four patients showed no response. There were no infectious or hemorrhagic complications, but partial hearing loss occurred in 7 patients and severe vomiting in 8 patients. High-dose intravenous cisplatin demonstrates substantial activity against malignant gliomas recurrent after chloroethylnitrosourea (CENU) failure.

AB - Twenty-one patients with recurrent malignant glioma who had failed prior chemotherapy with nitrosoureas were treated with high-dose intravenous cisplatin on days 1 and 8 of successive 4 week cycles. Fourteen patients were evaluable for response. Four patients showed partial responses; mean time to tumor progression (MTP) was 8 weeks. Six patients stabilized; MTP was 11 weeks. Four patients showed no response. There were no infectious or hemorrhagic complications, but partial hearing loss occurred in 7 patients and severe vomiting in 8 patients. High-dose intravenous cisplatin demonstrates substantial activity against malignant gliomas recurrent after chloroethylnitrosourea (CENU) failure.

KW - astrocytoma

KW - brain tumors

KW - chemotherapy

KW - cisplatin

KW - glioblastoma

KW - malignant glioma

UR - http://www.scopus.com/inward/record.url?scp=0026544396&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026544396&partnerID=8YFLogxK

U2 - 10.1007/BF00172671

DO - 10.1007/BF00172671

M3 - Article

VL - 12

SP - 187

EP - 191

JO - Journal of Neuro-Oncology

JF - Journal of Neuro-Oncology

SN - 0167-594X

IS - 2

ER -